Hervé Bachelez
Hervé Bachelez is an expert in Dermatology at Hôpital Saint-Louis (France). As of September 2026, ScienceLeadR ranks Hervé Bachelez in the top 1% of experts worldwide for Psoriasis, Sexually Transmitted Diseases and Skin Diseases, Papulosquamous. Hervé Bachelez has authored 446 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 2 of them ongoing. SLR score: 1,436 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Public Health - Immunology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1989 - 2026
Number : 446
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype. PMID 42424135 — genes, rna editing, psoriasis, rna | J Exp Med | 2026 | 2 |
| Global burden of skin and subcutaneous disease across childhood and adolescence in 204 countries and territories, 1990-2021. PMID 42306339 — skin, epidemiology, cost of illness | JAAD Int | 2026 | 0 |
| Psoriasis flare-ups in non syndromic autosomal recessive epidermal differentiation disorders. PMID 42274354 — syphilis, psoriasis, dermatology | Br J Dermatol | 2026 | 0 |
| Switching from intravenous to subcutaneous infliximab in hidradenitis suppurativa: a French multicenter retrospective study. PMID 42134419 — retrospective studies, hidradenitis suppurativa, hidradenitis, dermatology, infliximab | J Am Acad Dermatol | 2026 | 0 |
| Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. PMID 42047557 — safety, drug-related side effects and adverse reactions, therapeutics, psoriasis | NEJM Evid | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase 3 Multicenter Randomized Double blind Placebo controlled and Deucravacitinib Active Comparator controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis 2023-505121-14-00 — safety, therapeutics, psoriasis | Phase 3 | Active not recruiting | 2024 |
| Cellular and Molecular Biomarkers in Patients With Lichen Planus NCT06451744 — skin, cells, epitopes, blood, biopsy, biomarkers, lichens, diagnosis, alphapapillomavirus, lichen planus, mucous membrane, wounds and injuries, membranes, human papillomavirus viruses | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map